Currently in the final stage of clinical trials, the Sputnik V vaccine is ready to enter Indonesia - News
- News Archive for 2020
- News Archive for 2019
- News Archive for 2018
- News Archive for 2017
- News Archive for 2016
- News Archive for 2015
- News Archive for 2014
- News Archive for 2013
- News Archive for 2012
- News Archive for 2011
- News Archive for 2010
- News Archive for 2009
- News Archive for 2008
- News Archive for 2007
- News Archive for 2006
- News Archive for 2005
- Publications in Media
Currently in the final stage of clinical trials, the Sputnik V vaccine is ready to enter Indonesia
Representative of the Russian Government in Indonesia through Ambassador Lyudmila Vorobieva stated that they are ready to cooperate with a number of parties in Indonesia in the supply of the Sputnik V vaccine.
"We are ready to work with the Indonesian government in this field. The Sputnik V vaccine is currently in the process of registration at BPOM Indonesia and the World Health Organization," Ambassador Lyudmila said.
In April 2020, President Joko Widodo held a telephone conversation with Russian President Vladimir Putin discussing efforts to increase cooperation in dealing with the corona virus pandemic. It was agreed between President Joko Widodo and President Vladimir Putin to increase contact between the two countries' health ministries.
On 17 September 2020, the Russian Government through its Ambassador in Indonesia, Lyudmila Vorobieva, officially contacted the Ministry of Health of the Republic of Indonesia to offer the use and further development of the corona virus vaccine, Sputnik V.
Sputnik V is an anti-Covid-19 vaccine developed by the Gamaleya Research Institute and the Russian Ministry of Defense based in Moscow. Russian President Vladimir Putin claims that the vaccine his country found has a 95% effectiveness rate and is safe in its use.
Sputnik V is the world's first registered vaccine based on a well-studied human adenoviral bivector based platform that is safe for use. Vector is a transport technology that carries the genetics of the corona virus into cells, so that antibodies are formed in the human body. Because Sputnik V uses bivector technology, it provides stronger and longer lasting immune results than that of the vaccines developed by other pharmaceutical companies, which use monovector technology. Currently, Sputnik V is among the top 10 vaccine candidates nearing the end of clinical trials and ready for mass production and to be registered with the World Health Organization (WHO).
"Because we have the same view with the Indonesian government that all countries should have access to this vaccine. Therefore, in this case, we are ready to assist the Government of Indonesia in providing the Sputnik vaccine, " Ambassador Lyudmila concluded.